Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver.

Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V.

Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3510-5. doi: 10.1073/pnas.1112209109. Epub 2012 Jan 30.

2.

Resolving controversies on the path to Alzheimer's therapeutics.

Selkoe DJ.

Nat Med. 2011 Sep 7;17(9):1060-5. doi: 10.1038/nm.2460. Erratum in: Nat Med. 2011 Nov;17(11):1521. Nat Med. 2011 Dec;17(12):1693.

PMID:
21900936
3.

Modified immunotherapies against Alzheimer's disease: toward safer and effective amyloid clearance.

Wang YJ, Zhou HD, Zhou XF.

J Alzheimers Dis. 2010;21(4):1065-75. Review.

PMID:
21504118
4.

Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4.

Pollen DA, Baker S, Hinerfeld D, Swearer J, Evans BA, Evans JE, Caselli R, Rogaeva E, St George-Hyslop P, Moonis M.

Alzheimers Res Ther. 2010 Oct 29;2(5):31. doi: 10.1186/alzrt55. No abstract available.

5.

Lipoprotein receptors--an evolutionarily ancient multifunctional receptor family.

Dieckmann M, Dietrich MF, Herz J.

Biol Chem. 2010 Nov;391(11):1341-63. doi: 10.1515/BC.2010.129. Review.

6.

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

Lemere CA, Masliah E.

Nat Rev Neurol. 2010 Feb;6(2):108-19. doi: 10.1038/nrneurol.2009.219. Review. Erratum in: Nat Rev Neurol. 2010 Apr;6(4):183. Nat Rev Neurol. 2010 Jun;6(6):296.

7.

The secretases: enzymes with therapeutic potential in Alzheimer disease.

De Strooper B, Vassar R, Golde T.

Nat Rev Neurol. 2010 Feb;6(2):99-107. doi: 10.1038/nrneurol.2009.218. Review.

8.

Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention.

Dasilva KA, Shaw JE, McLaurin J.

Exp Neurol. 2010 Jun;223(2):311-21. doi: 10.1016/j.expneurol.2009.08.032. Epub 2009 Sep 8. Review.

PMID:
19744483
9.

Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Deane R, Bell RD, Sagare A, Zlokovic BV.

CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-30. Review.

10.

Will anti-amyloid therapies work for Alzheimer's disease?

St George-Hyslop PH, Morris JC.

Lancet. 2008 Jul 19;372(9634):180-2. doi: 10.1016/S0140-6736(08)61047-8. No abstract available.

PMID:
18640437
11.

Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease.

Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ.

Curr Alzheimer Res. 2008 Apr;5(2):212-24. Review.

PMID:
18393806
12.
13.

Clearance of amyloid-beta by circulating lipoprotein receptors.

Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV.

Nat Med. 2007 Sep;13(9):1029-31. Epub 2007 Aug 12.

14.

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.

Haass C, Selkoe DJ.

Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12. Review.

PMID:
17245412
15.

Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.

Wang YJ, Zhou HD, Zhou XF.

Drug Discov Today. 2006 Oct;11(19-20):931-8. Epub 2006 Sep 7. Review.

PMID:
16997144
16.

Withanoside IV and its active metabolite, sominone, attenuate Abeta(25-35)-induced neurodegeneration.

Kuboyama T, Tohda C, Komatsu K.

Eur J Neurosci. 2006 Mar;23(6):1417-26.

PMID:
16553605
17.

Neuritic regeneration and synaptic reconstruction induced by withanolide A.

Kuboyama T, Tohda C, Komatsu K.

Br J Pharmacol. 2005 Apr;144(7):961-71.

18.

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Hardy J, Selkoe DJ.

Science. 2002 Jul 19;297(5580):353-6. Review. Erratum in: Science 2002 Sep 27;297(5590):2209.

PMID:
12130773

Supplemental Content

Support Center